UNITED STATES OF AMERICA Docket No.: DEAV2002/0063 US NP

## DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

	My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:			
	INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IKB KINASE			
	and the specification of wl (check one)	was filed on and was amended o was described and	Aventis Docket No. <b>DEAV2002/0063 US NP)</b> as U.S. Application Number on (if applicable). claimed in PCT Int'l Application Number filed on ended under PCT Article 19 on (if any).	
	I/We hereby state that I/We have reviewed and understand the contents of the above identified specificati including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us be material to patentability as defined in 37 C.F.R. 1.56.			
	I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:			
Foreign	10237722.7	Germany	17/August/2002	
Priority:	Number .	Country	Day/Month/Year Filed	
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed	
$\boxtimes$	I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:			
	60/434,749 Number	December 19, 2002 Filing Date		
	I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United State application(s) or international application designating the United States listed below and, insofar as the subjunction of each of the claims of this application is not disclosed in the prior United States application in the man provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclosinformation which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 who became available between the filing date of the prior application and the national or PCT international filing date this application.			
	Application Serial No.	Filing Date	Status (Patented, Pending)	

Docket No.: DEAV2002/0063 US NP

Page 1 of 2

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): Additional names and signatures are attack	ched.
1. Full name: Olaf RITZELER	2. Full name: Gerhard JAEHNE
Signature:	Signature:
Date:	Date:
Country of Citizenship: Germany	Country of Citizenship: Germany
Residence: Bad Soden, Germany	Residence: Frankfurt, Germany
(City and State/City and Country only)	(City and State/City and Country only)
P. O. Address: Hubertushohe 6	P. O. Address: Seebachstrasse 22
65812 Bad Soden, Germany	65929 Frankfurt, Germany

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0063 US NP

Docket No.: DEAV2002/0063 US NP Page 2 of 2